Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 3,970 Cr.
- Current Price ₹ 694
- High / Low ₹ 1,021 / 608
- Stock P/E 49.8
- Book Value ₹ 148
- Dividend Yield 0.29 %
- ROCE 11.6 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 373 | 411 | 785 | 859 | 865 | 958 | 1,183 | |
| 322 | 356 | 687 | 760 | 755 | 836 | 1,044 | |
| Operating Profit | 51 | 54 | 99 | 99 | 110 | 122 | 139 |
| OPM % | 14% | 13% | 13% | 11% | 13% | 13% | 12% |
| 1 | 1 | 3 | 9 | 9 | 17 | 17 | |
| Interest | 5 | 4 | 5 | 18 | 14 | 2 | 13 |
| Depreciation | 10 | 6 | 7 | 11 | 11 | 17 | 36 |
| Profit before tax | 38 | 46 | 89 | 78 | 94 | 120 | 107 |
| Tax % | 26% | 26% | 25% | 26% | 27% | 25% | |
| 28 | 34 | 66 | 58 | 68 | 89 | 80 | |
| EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.63 | 13.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 7% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 11% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 14% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 98 | 133 | 199 | 220 | 666 | 756 | 791 |
| 54 | 45 | 176 | 237 | 244 | 329 | 318 | |
| 81 | 178 | 157 | 173 | 187 | 223 | 277 | |
| Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,443 |
| 73 | 79 | 161 | 161 | 164 | 637 | 653 | |
| CWIP | 0 | 7 | 0 | 22 | 339 | 21 | 7 |
| Investments | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| 172 | 282 | 322 | 435 | 593 | 647 | 723 | |
| Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,443 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 31 | 42 | 58 | 39 | 112 | 20 | |
| -6 | -20 | -188 | -88 | -472 | -100 | |
| -23 | -19 | 125 | 51 | 368 | 84 | |
| Net Cash Flow | 1 | 3 | -5 | 3 | 8 | 4 |
| Free Cash Flow | 27 | 23 | -21 | -39 | -165 | -141 |
| CFO/OP | 79% | 101% | 80% | 59% | 123% | 32% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 85 | 123 | 81 | 98 | 92 | 95 |
| Inventory Days | 84 | 107 | 63 | 67 | 68 | 94 |
| Days Payable | 92 | 132 | 84 | 102 | 111 | 119 |
| Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 | 70 |
| Working Capital Days | 45 | 39 | 23 | 44 | 58 | 65 |
| ROCE % | 28% | 33% | 21% | 15% | 12% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio (FATR) - Standalone Base x |
|
||||
| Installed Capacity - Capsules Million Units |
|||||
| Installed Capacity - Tablets Million Units |
|||||
| Net Working Capital Days Days |
|||||
| Actual Production - Capsules Million Units |
|||||
| Actual Production - Tablets Million Units |
|||||
| CDMO Customers Count Units |
|||||
| Export Presence (Count of Countries) Units |
|||||
| Number of CDMO Products Sold Units |
|||||
| Indian Formulation CDMO Market Share % |
|||||
| Pharmacy Touchpoints in India Units |
|||||
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Depositories and Participants) Regulations, 2018, we are enclosing herewith a copy of the certificate dated 07th April, 2026, received from KFin Technologies Limited, Registrar & …
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 2 Apr
-
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
1 Apr - 25,00,000 shares (4.37%) pledged to Vistra ITCL on March 11, 2026.
-
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
27 Mar - Vistra ITCL pledged 36,54,610 Innova Captab shares (6.38%) on 11-Mar-2026.
- Closure of Trading Window 25 Mar
Concalls
-
Feb 2026TranscriptPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain